Ixazomib (Ninlaro®), lenalidomide (Revlimid®) and dexamethasone
Daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone
Isatuximab (Sarclisa®), pomalidomide (Imnovid®) and dexamethasone.
Daratumumab (Darzalex®), lenalidomide (Revlimid®) and dexamethasone
Belantamab Mafodotin (Blenrep®)
Ciltacabtagene autoleucel (Cilta-Cel) CAR-T treatment
Daratumumab (Darzalex®) in combination with bortezomib (Velcade®), cyclophosphamide and dexamethasone for AL amyloidosis
We will continue to work with patients, their families and carers, and clinicians to advocate for the approval of effective, new treatments. We will also continue to update patients and healthcare professionals on the progress of these HTAs.
If you would like more information on HTA processes, upcoming treatment appraisals, or Myeloma UK’s access work, contact the Policy Team.